Risperidone LA is under clinical development by Nanomi and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Risperidone LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Risperidone LA overview
Risperidone is under development for the treatment of schizophrenia. It is administered through intramuscular route and acts by targeting 5-hydroxytryptamine receptor 2A (5 HT2A) and D2 dopamine receptor (DRD2).
Nanomi, a subsidiary of Lupin Ltd, is a drug delivery company. It manufactures and develops microspheres and nanoparticles. The company utilizes Microsieve, a proprietary micro-filtration technology to produce its products. Its products are used in encapsulation of various injectables and pharmaceutical compounds such as antibodies, hormones, small molecules and cytostatic compounds. Nanomi is headquartered in Oldenzaal, Overijssel, the Netherlands.
For a complete picture of Risperidone LA’s drug-specific PTSR and LoA scores, buy the report here.